**Recent executive actions and administrative proceedings have shaped trader views on federal cannabis rescheduling.** President Trump's December 2025 executive order directed expedited movement of marijuana to Schedule III under the Controlled Substances Act. In April 2026, the Department of Justice immediately reclassified FDA-approved marijuana products and state-licensed medical cannabis to Schedule III while launching an expedited hearing process for broader rescheduling of all marijuana from Schedule I. That hearing began June 29, 2026, and was scheduled to conclude by mid-July, with firm procedural deadlines intended to accelerate a potential final DEA rule. Traders monitor hearing outcomes, any resulting notice-and-comment rulemaking, and related agency actions for signals on full rescheduling timelines, as these directly influence implied probabilities in related prediction markets.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · Actualizado$795,647 Vol.
31 mar 2026
30 de septiembre
14%
31 de diciembre
27%
$795,647 Vol.
30 de septiembre
$0 Vol.
14%
31 de diciembre
$186,077 Vol.
27%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.**Recent executive actions and administrative proceedings have shaped trader views on federal cannabis rescheduling.** President Trump's December 2025 executive order directed expedited movement of marijuana to Schedule III under the Controlled Substances Act. In April 2026, the Department of Justice immediately reclassified FDA-approved marijuana products and state-licensed medical cannabis to Schedule III while launching an expedited hearing process for broader rescheduling of all marijuana from Schedule I. That hearing began June 29, 2026, and was scheduled to conclude by mid-July, with firm procedural deadlines intended to accelerate a potential final DEA rule. Traders monitor hearing outcomes, any resulting notice-and-comment rulemaking, and related agency actions for signals on full rescheduling timelines, as these directly influence implied probabilities in related prediction markets.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Mercado abierto: Feb 7, 2026, 5:04 PM ET
Volumen
$795,647Fecha de finalización
31 mar 2026Mercado abierto
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.**Recent executive actions and administrative proceedings have shaped trader views on federal cannabis rescheduling.** President Trump's December 2025 executive order directed expedited movement of marijuana to Schedule III under the Controlled Substances Act. In April 2026, the Department of Justice immediately reclassified FDA-approved marijuana products and state-licensed medical cannabis to Schedule III while launching an expedited hearing process for broader rescheduling of all marijuana from Schedule I. That hearing began June 29, 2026, and was scheduled to conclude by mid-July, with firm procedural deadlines intended to accelerate a potential final DEA rule. Traders monitor hearing outcomes, any resulting notice-and-comment rulemaking, and related agency actions for signals on full rescheduling timelines, as these directly influence implied probabilities in related prediction markets.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Volumen
$795,647Fecha de finalización
31 mar 2026Mercado abierto
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...**Recent executive actions and administrative proceedings have shaped trader views on federal cannabis rescheduling.** President Trump's December 2025 executive order directed expedited movement of marijuana to Schedule III under the Controlled Substances Act. In April 2026, the Department of Justice immediately reclassified FDA-approved marijuana products and state-licensed medical cannabis to Schedule III while launching an expedited hearing process for broader rescheduling of all marijuana from Schedule I. That hearing began June 29, 2026, and was scheduled to conclude by mid-July, with firm procedural deadlines intended to accelerate a potential final DEA rule. Traders monitor hearing outcomes, any resulting notice-and-comment rulemaking, and related agency actions for signals on full rescheduling timelines, as these directly influence implied probabilities in related prediction markets.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · Actualizado
Cuidado con los enlaces externos.
Cuidado con los enlaces externos.
Preguntas frecuentes